Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 27 | 2025 | 70 | 11.720 |
Why?
|
| Hypertension | 11 | 2025 | 61 | 5.670 |
Why?
|
| Medicare Part C | 11 | 2024 | 31 | 5.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2025 | 21 | 4.630 |
Why?
|
| Diabetes Mellitus | 8 | 2025 | 33 | 3.820 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 15 | 3.560 |
Why?
|
| Motivational Interviewing | 5 | 2023 | 11 | 3.510 |
Why?
|
| Aged | 36 | 2025 | 859 | 3.460 |
Why?
|
| Retrospective Studies | 35 | 2024 | 382 | 3.390 |
Why?
|
| United States | 34 | 2025 | 521 | 3.320 |
Why?
|
| Antihypertensive Agents | 6 | 2025 | 16 | 3.200 |
Why?
|
| Hyperlipidemias | 5 | 2025 | 9 | 3.100 |
Why?
|
| Smoking Cessation | 8 | 2016 | 137 | 2.860 |
Why?
|
| Humans | 66 | 2025 | 5476 | 2.710 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 44 | 2.640 |
Why?
|
| Anticoagulants | 4 | 2024 | 15 | 2.490 |
Why?
|
| Female | 47 | 2025 | 2811 | 2.260 |
Why?
|
| Male | 37 | 2025 | 2765 | 2.000 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 107 | 1.850 |
Why?
|
| Aged, 80 and over | 14 | 2025 | 320 | 1.730 |
Why?
|
| Smoking | 5 | 2016 | 94 | 1.700 |
Why?
|
| Obesity | 6 | 2023 | 118 | 1.670 |
Why?
|
| Middle Aged | 23 | 2024 | 1098 | 1.620 |
Why?
|
| Drug Therapy, Combination | 5 | 2025 | 26 | 1.600 |
Why?
|
| Medicare | 12 | 2024 | 79 | 1.570 |
Why?
|
| Stroke | 2 | 2024 | 53 | 1.560 |
Why?
|
| Texas | 14 | 2025 | 190 | 1.450 |
Why?
|
| Medicare Part D | 2 | 2021 | 7 | 1.380 |
Why?
|
| Hypoglycemic Agents | 3 | 2025 | 15 | 1.300 |
Why?
|
| Antipsychotic Agents | 6 | 2024 | 48 | 1.200 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 18 | 1.190 |
Why?
|
| Weight Gain | 4 | 2024 | 28 | 1.150 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 5 | 1.130 |
Why?
|
| Rivaroxaban | 2 | 2024 | 6 | 1.130 |
Why?
|
| Pyridones | 2 | 2024 | 8 | 1.120 |
Why?
|
| Pyrazoles | 2 | 2024 | 19 | 1.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2025 | 16 | 1.090 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2025 | 17 | 1.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 8 | 1.070 |
Why?
|
| Markov Chains | 2 | 2024 | 18 | 1.070 |
Why?
|
| Administration, Oral | 6 | 2025 | 35 | 1.070 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2016 | 47 | 1.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 20 | 1.060 |
Why?
|
| Bupropion | 2 | 2016 | 8 | 1.000 |
Why?
|
| Varenicline | 2 | 2016 | 8 | 1.000 |
Why?
|
| Hospitalization | 3 | 2020 | 38 | 0.990 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 17 | 0.890 |
Why?
|
| Hemorrhage | 1 | 2024 | 5 | 0.890 |
Why?
|
| Nicotinic Agonists | 2 | 2015 | 14 | 0.880 |
Why?
|
| Adult | 22 | 2024 | 1683 | 0.880 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 3 | 0.880 |
Why?
|
| Logistic Models | 9 | 2021 | 69 | 0.870 |
Why?
|
| Warfarin | 2 | 2022 | 3 | 0.830 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 37 | 0.820 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 1 | 0.740 |
Why?
|
| Cancer Survivors | 2 | 2018 | 15 | 0.740 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 10 | 0.710 |
Why?
|
| Health Care Costs | 1 | 2020 | 11 | 0.680 |
Why?
|
| Adolescent | 14 | 2024 | 806 | 0.680 |
Why?
|
| Primary Health Care | 1 | 2021 | 46 | 0.680 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 3 | 0.670 |
Why?
|
| Benchmarking | 1 | 2020 | 13 | 0.660 |
Why?
|
| Patient Readmission | 1 | 2020 | 7 | 0.660 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 26 | 0.660 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 284 | 0.650 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 73 | 0.630 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 2 | 0.610 |
Why?
|
| Young Adult | 10 | 2024 | 850 | 0.600 |
Why?
|
| Drug Combinations | 4 | 2020 | 25 | 0.600 |
Why?
|
| Risk Factors | 8 | 2024 | 184 | 0.590 |
Why?
|
| Smoking Prevention | 2 | 2016 | 15 | 0.530 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 3 | 0.520 |
Why?
|
| Schizophrenia | 1 | 2016 | 8 | 0.520 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 13 | 0.510 |
Why?
|
| Arabs | 1 | 2015 | 2 | 0.500 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 3 | 0.490 |
Why?
|
| Health Behavior | 1 | 2015 | 38 | 0.490 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 49 | 0.470 |
Why?
|
| Tobacco Products | 1 | 2015 | 39 | 0.470 |
Why?
|
| Physicians | 3 | 2016 | 18 | 0.450 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 97 | 0.450 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 21 | 0.440 |
Why?
|
| Telephone | 3 | 2019 | 13 | 0.420 |
Why?
|
| Risk-Taking | 2 | 2012 | 16 | 0.400 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 90 | 0.400 |
Why?
|
| Body Mass Index | 6 | 2024 | 100 | 0.400 |
Why?
|
| Disease Management | 1 | 2012 | 6 | 0.390 |
Why?
|
| Universities | 1 | 2012 | 80 | 0.360 |
Why?
|
| Social Class | 2 | 2024 | 22 | 0.330 |
Why?
|
| HIV Infections | 3 | 2023 | 115 | 0.330 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 30 | 0.330 |
Why?
|
| Students | 1 | 2012 | 122 | 0.330 |
Why?
|
| Child | 8 | 2024 | 657 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 13 | 0.310 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 14 | 0.310 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 277 | 0.290 |
Why?
|
| Prospective Studies | 2 | 2019 | 132 | 0.280 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 12 | 0.280 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 148 | 0.270 |
Why?
|
| Ambulatory Care | 2 | 2020 | 10 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 26 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 53 | 0.240 |
Why?
|
| Comorbidity | 2 | 2016 | 49 | 0.240 |
Why?
|
| Pharmacists | 2 | 2016 | 41 | 0.240 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 7 | 0.230 |
Why?
|
| Health Status Disparities | 1 | 2024 | 11 | 0.230 |
Why?
|
| Delirium | 1 | 2024 | 7 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 13 | 0.230 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 10 | 0.230 |
Why?
|
| Dabigatran | 1 | 2024 | 2 | 0.220 |
Why?
|
| Thalidomide | 1 | 2024 | 3 | 0.220 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 10 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 16 | 0.220 |
Why?
|
| Qualitative Research | 1 | 2024 | 47 | 0.220 |
Why?
|
| Treatment Outcome | 2 | 2022 | 212 | 0.220 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 52 | 0.200 |
Why?
|
| Mental Disorders | 1 | 2023 | 52 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 1 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 4 | 0.200 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 3 | 0.200 |
Why?
|
| Metformin | 1 | 2022 | 9 | 0.190 |
Why?
|
| Insulin Resistance | 1 | 2022 | 9 | 0.190 |
Why?
|
| Buprenorphine | 1 | 2022 | 8 | 0.190 |
Why?
|
| Tamoxifen | 2 | 2020 | 12 | 0.190 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 8 | 0.190 |
Why?
|
| Confidence Intervals | 2 | 2012 | 6 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 20 | 0.190 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 8 | 0.190 |
Why?
|
| Diabetes Complications | 1 | 2022 | 5 | 0.190 |
Why?
|
| Health Surveys | 2 | 2012 | 13 | 0.190 |
Why?
|
| Odds Ratio | 2 | 2012 | 19 | 0.190 |
Why?
|
| Sexual Behavior | 2 | 2013 | 29 | 0.190 |
Why?
|
| Military Personnel | 2 | 2013 | 23 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2021 | 29 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 35 | 0.180 |
Why?
|
| Forecasting | 1 | 2021 | 19 | 0.180 |
Why?
|
| Medicaid | 1 | 2021 | 29 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 74 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 8 | 0.170 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 25 | 0.170 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 3 | 0.170 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 2 | 0.170 |
Why?
|
| Lactulose | 1 | 2020 | 2 | 0.170 |
Why?
|
| Neomycin | 1 | 2020 | 2 | 0.170 |
Why?
|
| Recurrence | 1 | 2020 | 26 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 119 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2019 | 28 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 4 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 4 | 0.160 |
Why?
|
| Blood Glucose | 3 | 2023 | 31 | 0.160 |
Why?
|
| Intention | 2 | 2016 | 19 | 0.160 |
Why?
|
| Psychological Theory | 2 | 2016 | 22 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2019 | 40 | 0.150 |
Why?
|
| Age Factors | 1 | 2019 | 75 | 0.150 |
Why?
|
| Standard of Care | 1 | 2018 | 2 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2018 | 131 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 9 | 0.150 |
Why?
|
| Sex Factors | 1 | 2019 | 81 | 0.150 |
Why?
|
| Quinolines | 1 | 2019 | 21 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 17 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 8 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 9 | 0.150 |
Why?
|
| Perception | 2 | 2022 | 32 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 183 | 0.140 |
Why?
|
| Linear Models | 1 | 2017 | 60 | 0.130 |
Why?
|
| Hydrocodone | 1 | 2016 | 3 | 0.130 |
Why?
|
| Controlled Substances | 1 | 2016 | 4 | 0.130 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 8 | 0.130 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 1 | 0.130 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2016 | 2 | 0.120 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 6 | 0.120 |
Why?
|
| Health Personnel | 1 | 2016 | 22 | 0.120 |
Why?
|
| Risk | 1 | 2015 | 34 | 0.120 |
Why?
|
| Incidence | 1 | 2015 | 33 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 9 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2015 | 19 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 28 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2014 | 14 | 0.110 |
Why?
|
| Neoplasms | 1 | 2016 | 99 | 0.110 |
Why?
|
| Cholinergic Antagonists | 2 | 2024 | 20 | 0.110 |
Why?
|
| Overweight | 1 | 2014 | 41 | 0.110 |
Why?
|
| Self Report | 1 | 2014 | 72 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 3 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 6 | 0.100 |
Why?
|
| Cholesterol | 2 | 2023 | 18 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 2 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2023 | 96 | 0.100 |
Why?
|
| Jordan | 1 | 2012 | 5 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 4 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 3 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 3 | 0.090 |
Why?
|
| Vitamin D | 1 | 2011 | 4 | 0.090 |
Why?
|
| Public Health | 1 | 2012 | 22 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 4 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 22 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2024 | 10 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 6 | 0.060 |
Why?
|
| Health Status | 1 | 2024 | 30 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2024 | 24 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2024 | 18 | 0.060 |
Why?
|
| Aripiprazole | 1 | 2024 | 3 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 3 | 0.050 |
Why?
|
| Survival Rate | 1 | 2023 | 16 | 0.050 |
Why?
|
| Research | 1 | 2023 | 10 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2024 | 187 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 39 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2023 | 31 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 7 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 82 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 7 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 3 | 0.050 |
Why?
|
| Opiate Substitution Treatment | 1 | 2022 | 9 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 6 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 21 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 19 | 0.050 |
Why?
|
| Nigeria | 2 | 2013 | 7 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2022 | 19 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2013 | 24 | 0.050 |
Why?
|
| Cognition | 1 | 2023 | 174 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 6 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 5 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 9 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 14 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2020 | 18 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 15 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 12 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 55 | 0.040 |
Why?
|
| Registries | 1 | 2018 | 24 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 3 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 3 | 0.030 |
Why?
|
| Middle East | 1 | 2016 | 1 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 32 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 1 | 0.030 |
Why?
|
| Communication | 1 | 2016 | 33 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 8 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 18 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 1 | 0.030 |
Why?
|
| Heart Failure | 1 | 2016 | 32 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 5 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 3 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 8 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 1 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 19 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 72 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 6 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 43 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 35 | 0.020 |
Why?
|